SG11201602477YA - Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof - Google Patents

Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof

Info

Publication number
SG11201602477YA
SG11201602477YA SG11201602477YA SG11201602477YA SG11201602477YA SG 11201602477Y A SG11201602477Y A SG 11201602477YA SG 11201602477Y A SG11201602477Y A SG 11201602477YA SG 11201602477Y A SG11201602477Y A SG 11201602477YA SG 11201602477Y A SG11201602477Y A SG 11201602477YA
Authority
SG
Singapore
Prior art keywords
compound
pharmaceutical use
somatostatin receptor
agonistic activity
receptor agonistic
Prior art date
Application number
SG11201602477YA
Other languages
English (en)
Inventor
Akiharu Ishida
Takeshi Matsushita
Tetsuya Sekiguchi
Yasuyuki Okabe
Tatsuya Komagata
Takuya Nishio
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of SG11201602477YA publication Critical patent/SG11201602477YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11201602477YA 2013-09-30 2014-09-29 Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof SG11201602477YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013205027 2013-09-30
JP2013268902 2013-12-26
PCT/JP2014/075794 WO2015046482A1 (ja) 2013-09-30 2014-09-29 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
SG11201602477YA true SG11201602477YA (en) 2016-05-30

Family

ID=52743606

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201602477YA SG11201602477YA (en) 2013-09-30 2014-09-29 Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof

Country Status (21)

Country Link
US (1) US9643951B2 (es)
EP (1) EP3053916B1 (es)
JP (1) JP6380402B2 (es)
KR (1) KR20160062023A (es)
CN (1) CN105593221B (es)
AU (1) AU2014325078B2 (es)
BR (1) BR112016007078A2 (es)
CA (1) CA2925651A1 (es)
DK (1) DK3053916T3 (es)
ES (1) ES2716151T3 (es)
HK (1) HK1223356A1 (es)
HU (1) HUE043374T2 (es)
IL (1) IL244813A0 (es)
MX (1) MX2016004088A (es)
PH (1) PH12016500573A1 (es)
PL (1) PL3053916T3 (es)
PT (1) PT3053916T (es)
RU (1) RU2666352C2 (es)
SG (1) SG11201602477YA (es)
TW (1) TWI628175B (es)
WO (1) WO2015046482A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221279T1 (hr) 2016-07-14 2022-12-23 Crinetics Pharmaceuticals, Inc. Modulatori somatostatina i njihove uporabe
US20200000816A1 (en) * 2017-02-08 2020-01-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
KR20190121404A (ko) * 2017-03-16 2019-10-25 크리네틱스 파마슈티칼스, 인크. 소마토스타틴 조절제 및 이의 용도
WO2019023278A1 (en) 2017-07-25 2019-01-31 Crinetics Pharmaceuticals, Inc. MODULATORS OF SOMATOSTATIN AND USES THEREOF
MX2020007586A (es) 2018-01-17 2020-09-03 Crinetics Pharmaceuticals Inc Proceso de fabricacion de moduladores de somatostatina.
WO2019157458A1 (en) * 2018-02-12 2019-08-15 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
WO2019240246A1 (ja) * 2018-06-15 2019-12-19 小野薬品工業株式会社 ピペリジノール誘導体の新規な塩および新規結晶形
US10696689B2 (en) 2018-09-18 2020-06-30 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
TW202115008A (zh) * 2019-08-14 2021-04-16 美商克林提克斯醫藥股份有限公司 非肽生長抑制素(somatostatin)5型受體激動劑及其用途
JP2023540137A (ja) 2020-09-09 2023-09-21 クリネティックス ファーマシューティカルズ,インク. ソマトスタチン調節因子の製剤
JP2024506715A (ja) 2021-02-17 2024-02-14 クリネティックス ファーマシューティカルズ,インク. ソマトスタチンモジュレーターの結晶形態
CN116789674A (zh) * 2022-08-24 2023-09-22 杭州高光制药有限公司 Nlrp3炎性小体抑制剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) * 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) * 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
AR029876A1 (es) 1998-05-11 2003-07-23 Takeda Pharmaceutical Compuesto de acido oxiiminoalcanoilo, composicion farmaceutica y agente para controlar receptores relacionados con retinoide que lo comprenden y su uso
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU7556800A (en) 1999-10-07 2001-05-10 Tadeka Chemical Industries, Ltd. Amine derivatives
SK6432002A3 (en) 1999-11-10 2003-02-04 Takeda Chemical Industries Ltd 5-Membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
FR2802206B1 (fr) 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
WO2001082925A1 (fr) 2000-04-28 2001-11-08 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
AR044852A1 (es) * 2003-06-24 2005-10-05 Novartis Ag Una composicion farmaceutica para la administracion parenteral que comprende un analogo de somatostatina
US20090196912A1 (en) 2004-07-30 2009-08-06 Gpc Botech Ag Pyridinylamines
CN101258152A (zh) 2005-07-04 2008-09-03 阿斯利康(瑞典)有限公司 作为pde4抑制剂用于治疗炎症和免疫疾病的吡啶并嘧啶衍生物
TW200726767A (en) 2005-07-04 2007-07-16 Astrazeneca Ab Chemical compounds 2
CA2644929A1 (en) 2006-03-13 2008-05-02 Merck & Co., Inc. Somatostatin agonists
JP2010500391A (ja) * 2006-08-15 2010-01-07 エフ.ホフマン−ラ ロシュ アーゲー フェニル、ピリジン及びキノリン誘導体
GB0818241D0 (en) 2008-10-06 2008-11-12 Cancer Res Technology Compounds and their use
EP2871179A4 (en) 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES

Also Published As

Publication number Publication date
AU2014325078B2 (en) 2018-10-25
AU2014325078A1 (en) 2016-04-21
PL3053916T3 (pl) 2019-06-28
MX2016004088A (es) 2016-06-06
PH12016500573B1 (en) 2016-07-04
EP3053916A4 (en) 2017-03-08
US9643951B2 (en) 2017-05-09
PH12016500573A1 (en) 2016-07-04
CA2925651A1 (en) 2015-04-02
EP3053916B1 (en) 2019-01-30
DK3053916T3 (en) 2019-04-15
ES2716151T3 (es) 2019-06-10
HUE043374T2 (hu) 2019-08-28
RU2016111659A3 (es) 2018-03-20
TWI628175B (zh) 2018-07-01
RU2016111659A (ru) 2017-11-13
HK1223356A1 (zh) 2017-07-28
WO2015046482A1 (ja) 2015-04-02
PT3053916T (pt) 2019-03-26
JPWO2015046482A1 (ja) 2017-03-09
BR112016007078A2 (pt) 2017-12-12
US20160311794A1 (en) 2016-10-27
JP6380402B2 (ja) 2018-08-29
CN105593221A (zh) 2016-05-18
EP3053916A1 (en) 2016-08-10
RU2666352C2 (ru) 2018-09-07
KR20160062023A (ko) 2016-06-01
IL244813A0 (en) 2016-05-31
CN105593221B (zh) 2017-09-22
TW201602092A (zh) 2016-01-16

Similar Documents

Publication Publication Date Title
IL244813A0 (en) A compound with agonistic activity for the somatostatin receptor and its medicinal use
EP2871179A4 (en) CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
IL238238A0 (en) Il-6 antagonists and their use
HK1254296A1 (zh) 治療性化合物和其用途
GB201320729D0 (en) Therapeutic compounds and their use
IL268444A (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
IL245471B (en) Fluorinated compounds as alpha v integrin receptor antagonists
HK1217092A1 (zh) 治療性化合物及其用途
HRP20181536T1 (hr) Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora
EP3006431A4 (en) TIZOXANID CARBAMATE AND PHARMACEUTICAL USE THEREOF
HK1219691A1 (zh) 醫藥組成物及其用途
GB201311361D0 (en) Compounds and their therapeutic use
GB201308736D0 (en) Compounds and their therapeutic use
EP3065736A4 (en) Glucagon receptor antagonist compounds, compositions thereof, and methods of use
HK1216101A1 (zh) 用作促性腺激素釋放激素受體拮抗劑的螺二氫吲哚衍生物
EP2986627A4 (en) EPH-A RECEPTOR INHIBITORS AND USES THEREOF
GB201307049D0 (en) Catalysts and use thereof
EP2832732A4 (en) DRUG ENHANCING THE ACTIVITY OF PPAR AGONISTS
GB201317804D0 (en) Therapeutic compounds and their use
GB201316173D0 (en) Compounds and their therapeutic use
GB201304625D0 (en) New pharmaceutical composition
GB201307677D0 (en) Compounds and their therapeutic use